OmniSpirant Therapeutics announces a US patent grant for its “Extracellular Vesicles for Inhalation” technology with enhanced delivery properties.
GALWAY, GALWAY, IRELAND, August 16, 2024 /EINPresswire.com/ — OmniSpirant Therapeutics Receives Notice of Grant for US Patent Claiming a First-in-Class Regenerative Gene Therapy Platform for RNA-based Treatments.
OmniSpirant Therapeutics, an Irish biotech at the forefront of RNA delivery and therapeutics based on their regenerative gene therapy platform technology – OmniSomes, today announced that the US Patent Office has issued a Notice of Grant for a broad patent – “Extracellular Vesicles for Inhalation” that covers the use of compositions in which surface engineered stem cell exosomes have a broadly defined cargo and surface engineering to enhance their delivery properties.
